Citigroup Initiates Coverage On Coherus BioSciences with Buy Rating, Announces Price Target of $12
Portfolio Pulse from richadhand@benzinga.com
Citigroup analyst Robyn Karnauskas has initiated coverage on Coherus BioSciences (NASDAQ:CHRS) with a Buy rating and a price target of $12.
July 24, 2023 | 11:21 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Coherus BioSciences has been initiated with a Buy rating by Citigroup, with a price target of $12.
The Buy rating and price target set by Citigroup indicates a positive outlook for Coherus BioSciences. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100